JP6670244B2 - 免疫調節組成物及びその使用法 - Google Patents

免疫調節組成物及びその使用法 Download PDF

Info

Publication number
JP6670244B2
JP6670244B2 JP2016545781A JP2016545781A JP6670244B2 JP 6670244 B2 JP6670244 B2 JP 6670244B2 JP 2016545781 A JP2016545781 A JP 2016545781A JP 2016545781 A JP2016545781 A JP 2016545781A JP 6670244 B2 JP6670244 B2 JP 6670244B2
Authority
JP
Japan
Prior art keywords
individual
antigen
present disclosure
immunomodulatory composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016545781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507911A (ja
JP2017507911A5 (https=
Inventor
バビタ アグラワル
バビタ アグラワル
ラケシュ クマール
ラケシュ クマール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017507911A publication Critical patent/JP2017507911A/ja
Publication of JP2017507911A5 publication Critical patent/JP2017507911A5/ja
Application granted granted Critical
Publication of JP6670244B2 publication Critical patent/JP6670244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016545781A 2014-01-07 2015-01-07 免疫調節組成物及びその使用法 Active JP6670244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461924607P 2014-01-07 2014-01-07
US61/924,607 2014-01-07
PCT/IB2015/050108 WO2015104656A1 (en) 2014-01-07 2015-01-07 Immunomodulatory compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017507911A JP2017507911A (ja) 2017-03-23
JP2017507911A5 JP2017507911A5 (https=) 2018-06-07
JP6670244B2 true JP6670244B2 (ja) 2020-03-18

Family

ID=53523583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545781A Active JP6670244B2 (ja) 2014-01-07 2015-01-07 免疫調節組成物及びその使用法

Country Status (7)

Country Link
US (2) US10369205B2 (https=)
EP (1) EP3092001B1 (https=)
JP (1) JP6670244B2 (https=)
CN (1) CN106102771B (https=)
AU (1) AU2015205342B2 (https=)
CA (1) CA2935511C (https=)
WO (1) WO2015104656A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102193635B1 (ko) * 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
EP4480544A3 (en) * 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
CN108430482A (zh) * 2015-11-10 2018-08-21 伊丽莎白·麦克纳 细胞氧化还原水平的控制
CN112998905B (zh) 2016-03-02 2024-05-24 巴德股份有限公司 栓塞防护篮装置
WO2017201390A1 (en) * 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
KR20190125481A (ko) * 2017-03-17 2019-11-06 백심 아게 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
WO2018217764A1 (en) * 2017-05-22 2018-11-29 Kansas State University Research Foundation Microbiome transplantation
CN109157651A (zh) * 2018-09-06 2019-01-08 内蒙古科技大学包头医学院 具有免疫调节作用的组合物
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
EP3900736A1 (en) * 2020-04-24 2021-10-27 Klinikum der Universität München (KUM) Composition comprising a dna-degrading enzyme for use in a method for the treatment of immunosuppression after acute tissue injury
EP3904884A1 (en) * 2020-04-30 2021-11-03 Heinrich-Pette-Institut Method for predicting the course of a viral disease
CN115485565A (zh) * 2020-04-30 2022-12-16 莱布尼茨实验病毒学研究所 用于预测病毒疾病的过程的方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN111956798B (zh) * 2020-09-04 2023-03-03 江苏省农业科学院 用于猪伪狂犬灭活疫苗的复合免疫增强剂及其应用
CN112375712A (zh) * 2020-11-25 2021-02-19 昆明理工大学 一株乳酸乳球菌及其应用
CN113413486B (zh) * 2021-06-01 2022-05-10 中国科学院上海硅酸盐研究所 一种表面改性的聚醚醚酮材料及其制备方法和应用
CA3254356A1 (en) * 2022-04-07 2023-10-12 Veru Inc. METHODS OF TREATMENT OF VIRAL INFECTIONS OF INFLUENZA AND POXVIRUS
CN115975814B (zh) * 2022-09-02 2025-11-04 南方医科大学 一种聚酮化合物及其制备方法与应用
CN117323442B (zh) * 2023-08-30 2024-05-03 广东医科大学 一种巨噬细胞靶向二氧化锰纳米系统的制备方法及其应用
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614504A (en) 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5514688A (en) 1990-09-14 1996-05-07 Merrell Dow Pharmaceuticals Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5591748A (en) 1991-06-07 1997-01-07 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
US6210948B1 (en) 1992-06-09 2001-04-03 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
CA2090549C (en) 1992-06-09 2008-01-15 John Smit Bacterial surface protein expression
US5976864A (en) 1992-06-09 1999-11-02 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
US5843936A (en) 1996-06-28 1998-12-01 Bernstein; Lawrence R. Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes
IL129126A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
CA2363146A1 (en) * 1999-02-22 2000-08-31 Solomon Langermann Caulobacter lps immunoadjuvant
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2

Also Published As

Publication number Publication date
EP3092001A4 (en) 2017-08-02
CN106102771B (zh) 2021-06-29
JP2017507911A (ja) 2017-03-23
CA2935511A1 (en) 2015-07-16
US10369205B2 (en) 2019-08-06
CN106102771A (zh) 2016-11-09
EP3092001B1 (en) 2020-10-07
WO2015104656A1 (en) 2015-07-16
US10946082B2 (en) 2021-03-16
AU2015205342A1 (en) 2016-07-21
US20200054731A1 (en) 2020-02-20
AU2015205342B2 (en) 2020-01-23
CA2935511C (en) 2023-04-04
US20160317637A1 (en) 2016-11-03
EP3092001A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
US10946082B2 (en) Immunomodulatory compositions and methods of use thereof
US11701393B2 (en) Immunomodulatory compositions and methods of use thereof
RU2617058C2 (ru) Фармацевтическая композиция, содержащая комплекс полимерного носителя и переносимого вещества и по меньшей мере один белковый или пептидный антиген
JP5767201B2 (ja) 水中油型エマルジョンアジュバントを含むワクチン
JP2021534183A (ja) 免疫応答を刺激するための方法及び組成物
TW200908994A (en) Vaccine
US20110293658A1 (en) Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
JP2011516597A (ja) ワクチン
CN103990120B (zh) 抗感染剂及其用途
CN102470168A (zh) 新组合物
HK1227730A1 (en) Immunomodulatory compositions and methods of use thereof
HK1227730B (en) Immunomodulatory compositions and methods of use thereof
CA2996383C (en) Immunomodulatory compositions and methods of use thereof
US20180000926A1 (en) Methods of inducing an immune response to hepatitis c virus
HK40028670A (en) Liposomal formulations comprising saponin and methods of use
HK1159485B (en) Vaccine composition containing synthetic adjuvant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190731

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200228

R150 Certificate of patent or registration of utility model

Ref document number: 6670244

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250